| scholarly article | Q13442814 |
| P50 | author | Malte W Vetterlein | Q87782506 |
| P2093 | author name string | Sabine Riethdorf | |
| Heidi Schwarzenbach | |||
| Armin Soave | |||
| Michael Rink | |||
| P2860 | cites work | Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? | Q22251049 |
| Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer | Q24608906 | ||
| Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases | Q28289395 | ||
| Circulating tumor cells, disease progression, and survival in metastatic breast cancer | Q29619276 | ||
| Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer | Q30080026 | ||
| A place for precision medicine in bladder cancer: targeting the FGFRs | Q30249143 | ||
| Clonal origin of lymph node metastases in bladder carcinoma | Q33224290 | ||
| Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression | Q33787458 | ||
| Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis | Q33798322 | ||
| About the possible origin and mechanism of circulating DNA apoptosis and active DNA release | Q34100424 | ||
| Identification of p53 gene mutations in bladder cancers and urine samples | Q34104561 | ||
| Cell-free nucleic acids as biomarkers in cancer patients | Q34184393 | ||
| Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation | Q34441297 | ||
| Molecular profiling of single circulating tumor cells with diagnostic intention | Q34542660 | ||
| Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer | Q34790678 | ||
| Cancer micrometastases | Q34978121 | ||
| High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining | Q35604245 | ||
| Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer | Q35789737 | ||
| Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. | Q36120837 | ||
| Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients | Q36141581 | ||
| Extracellular Nucleic Acids in Urine: Sources, Structure, Diagnostic Potential | Q36175164 | ||
| Considerations in the development of circulating tumor cell technology for clinical use | Q36338628 | ||
| Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells | Q36393149 | ||
| Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer | Q36686671 | ||
| Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. | Q37182161 | ||
| Circulating tumor cells and bone marrow micrometastasis | Q37242269 | ||
| Circulating Biomarkers in Bladder Cancer | Q37530401 | ||
| Circulating tumor cells and circulating tumor DNA. | Q37952771 | ||
| Biomolecular predictors of urothelial cancer behavior and treatment outcomes | Q37987066 | ||
| Circulating nucleic acids and protease activities in blood of tumor patients | Q38002907 | ||
| The emerging role of circulating tumor cell detection in genitourinary cancer | Q38009457 | ||
| Microfluidics and circulating tumor cells | Q38069730 | ||
| Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent | Q38124003 | ||
| Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise? | Q38154011 | ||
| Real-time liquid biopsy in cancer patients: fact or fiction? | Q38154437 | ||
| Technologies for detection of circulating tumor cells: facts and vision | Q38154493 | ||
| Post-translational histone modifications in circulating nucleosomes as new biomarkers in colorectal cancer | Q38210818 | ||
| Do circulating tumor cells have a role in deciding on adjuvant chemotherapy after radical cystectomy? | Q38508249 | ||
| A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy | Q38817683 | ||
| Cancer Statistics, 2017. | Q39038674 | ||
| Characterization of single circulating tumor cells. | Q39275082 | ||
| Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients | Q39577973 | ||
| Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients | Q39612538 | ||
| Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study | Q39660094 | ||
| Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer | Q40069057 | ||
| Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. | Q40116927 | ||
| Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer | Q40433976 | ||
| EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. | Q40696118 | ||
| Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non-Muscle-Invasive Bladder Cancer | Q40817904 | ||
| Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells | Q41347908 | ||
| EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy | Q41472132 | ||
| Liquid biopsy: Potential and challenges. | Q42337624 | ||
| Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses? | Q42343423 | ||
| DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. | Q43540280 | ||
| Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. | Q44022435 | ||
| Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma | Q44045391 | ||
| Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer | Q44288628 | ||
| Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream | Q88219748 | ||
| Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. | Q45993982 | ||
| Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing | Q46302330 | ||
| Evaluation of Urinary DNA Methylation as a Marker for Recurrent Bladder Cancer: A 2-Center Prospective Study | Q47382277 | ||
| Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder. | Q47721218 | ||
| Analogous detection of circulating tumor cells using the AccuCyte® -CyteFinder® system and ISET system in patients with locally advanced and metastatic prostate cancer. | Q47760107 | ||
| The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer | Q49220712 | ||
| The landscape of genetics and biomarkers in bladder cancer | Q49479865 | ||
| Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer | Q49728493 | ||
| High Resolution Melting Analysis for Rapid Detection of PIK3CA Gene Mutations in Bladder Cancer: A Mutated Target for Cancer Therapy | Q49897856 | ||
| Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method | Q50060381 | ||
| Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. | Q50515553 | ||
| Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival. | Q50546557 | ||
| The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC). | Q50616289 | ||
| The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer. | Q50898962 | ||
| Circulating tumor cells in early bladder cancer: insight into micrometastatic disease. | Q51742759 | ||
| Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. | Q51953901 | ||
| Circulating tumor cells in bladder cancer: Emerging technologies and clinical implications foreseeing precision oncology. | Q52659966 | ||
| Hematogenous Tumor Cell Spread Following Standard Transurethral Resection of Bladder Carcinoma. | Q53120509 | ||
| Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients. | Q53165899 | ||
| p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. | Q53390985 | ||
| mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. | Q54377128 | ||
| Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. | Q54409514 | ||
| Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. | Q54443305 | ||
| Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements. | Q54546139 | ||
| Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. | Q54585164 | ||
| Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. | Q55043149 | ||
| Natural history, recurrence, and progression in superficial bladder cancer. | Q55154082 | ||
| The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder | Q58116506 | ||
| Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis | Q59396951 | ||
| Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer | Q62660487 | ||
| Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis | Q74826156 | ||
| TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples | Q77353045 | ||
| Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer | Q77522095 | ||
| Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer | Q78644435 | ||
| Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR | Q83126160 | ||
| EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016 | Q87711943 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | urology | Q105650 |
| reproductive medicine | Q351870 | ||
| bladder cancer | Q504775 | ||
| biomarker | Q864574 | ||
| P304 | page(s) | 61-75 | |
| P577 | publication date | 2019-02-01 | |
| P1433 | published in | Translational andrology and urology | Q27724139 |
| P1476 | title | The current role of circulating biomarkers in non-muscle invasive bladder cancer | |
| P478 | volume | 8 |
| Q90558380 | Current progress in the clinical use of circulating tumor cells as prognostic biomarkers | cites work | P2860 |
Search more.